Target product profile: A renaissance for its definition and use

Journal of Medical Marketing

Volumn 9, Issue 4, 2009, Pages 301-307

  Tebbey, Paul W ^a   Rink, Charles ^b  

^a Kolabri Consulting LLC   (United States)

^b IQVIA   (United States)

Author keywords

Commercial value; Pharmaceutical development; Strategic Evaluation Framework; Target Product Profile

Indexed keywords

EID: 75149168562     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1057/jmm.2009.34     Document Type: Article

References (20)

1. Frearson, J. A., Wyatt, P. G., Gilbert, I. H. and Fairlamb, A. H. (2007) Target assessment for antiparasitic drug discovery. Trends in Parasitology 23 (12): 589-595.
2. DiMasi, J. A. and Grabowski, H. G. (2007) The cost of biopharmaceutical R & D: Is biotech different? Managerial and Decision Economics 28 (4 - 5): 469-479.
3. Del Llano, J. (2007) Discussion point: Should governments buy drug patents? European Journal of Health Economics 8: 173-177.
4. Niles, S. (2008) 22nd annual report - 73 new medicines. MedAdNews 27 (3): 6-31.
5. Bowe, C. (2007) Pfizer takes a $ 2.8 billion writedown after failure of insulin treatment. Financial Times, London (UK), 19 October: 13.
6. Finn, B. M. and Sutherland, C. F. (2004) The pharmaceutical industry: Where it is, how it got here, where it needs to go, how to get there. International Journal of Medical Marketing 4 (4): 361-369.
7. Jack, A. (2009) GSK to shake-up research strategies. The Financial Times Limited, London, 9 June 2008, Vol.23: 18.
8. Rao, S. K. (2002) Pharmaceutical marketing in a new age. Marketing Health Services 22 (1): 7-12.
9. Cacciotti, J. and Shew, B. (2006) Pharma's next model. Pharmaceutical Executive (March).
10. Kennedy, A. (2008) Pharmaceutical Project Management , 2nd edn. New York: Informa Healthcare USA.
11. Shohet, S. (2005) De-risking novel therapeutic development - Time to stop blaming the molecule? Journal of Commercial Biotechnology 12 (1): 5-7.
12. Curry, S. and Brown, R. (2003) The target product profile as a planning tool in drug discovery research. Business Briefing: PharmaTech 2003, World Markets Research Centre, pp. 67 - 71.
13. Steinmetz, K. and Spack, E. (2009) The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurology 9 (1): S2.
14. Gad, S. (2007) Handbook of Pharmaceutical Biotechnology. Pharmaceutical Development Series, Vol.2. Hoboken, NJ: John Wiley and Sons.
15. US DHHS Food and Drug Administration. (2007) Draft guidance: Target Product profile - A strategic development process tool, http://www.fda.gov/cder/ guidance/6910dft.htm, accessed 7 October 2008.
16. Wilkins, M. (2003) Experimental Therapeutics. London, UK: Martin Dunitz - The Taylor & Francis Group.
17. Prahalad, C. K and Krishnan, M. S. (2008) The New Age of Innovation: Driving Cocreated Value through Global Networks. Columbus, OH, USA: McGraw-Hill , ISBN: 978-0071598286.
18. Don, R. (2005) Target product profile: Starting with patients in mind. DNDi newsletter, Vol.12, November http://www.dndi.org.
19. Yu, L. (2008) Pharmaceutical quality by design: Product and process development, understanding and control. Pharmaceutical Research 25 (4): 781-791.
20. Theodorou, A. (2004) Marketers, get to know your R & D colleagues: The rewards could be far reaching for you personally and for your organization. International Journal of Medical Marketing 4 (3): 298-300.